MedTrace Logo

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

NCT04838405 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2025-10-17

No results posted yet for this study

Summary

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

Conditions

Interventions

DRUG

CT-388

Synthetic Peptide

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Carmot Australia First Pty Ltd

    collaborator INDUSTRY

  • Carmot Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Carmot Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2024-06-18
Completion
2024-08-02

Countries

  • Australia
  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04838405 on ClinicalTrials.gov